atalyst Pharmaceuticalsannounced the appointment of William Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company’s President and CEO Richard Daly, and will serve as a member of the Company’s executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity. Since 2023, Dr. Andrews was the President, CEO and co-founder of Lighthouse Bio, a biopharmaceutical start-up focused on rare disease asset acquisition with the goal of new company formation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharma Holds 2025 Annual Stockholders Meeting
- Catalyst Pharma’s Strong Commercial Performance and Promising Revenue Guidance Justify Buy Rating
- Catalyst Pharma’s Strong Growth Prospects and Strategic Initiatives Drive Buy Rating
- Catalyst Pharmaceuticals Reports Record Q1 2025 Results
- Catalyst Pharmaceuticals Reports Robust Growth in Earnings Call